Assess and characterize the real-world cyclin-dependent kinase 4/6 inhibitor (CDKI) use in advanced/metastatic breast cancer (a/mBC), evaluate treatment persistence, and quantify CDKI dose adjustments in Portugal. This study used secondary data from the IQVIA database that collects data from hospital drug consumption. The study included 16 public hospitals across Portugal, for which data on consumption of drugs used in hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2-) a/mBC treatment was available. Patient selection was based on a set of criteria considering all patients with treatments in the a/mBC setting with use of at least one CDKI from November 2018 to May 2023.
Study Type
OBSERVATIONAL
Enrollment
1,926
Novartis
East Hanover, New Jersey, United States
Number of Patients Treated With a CDKI Between November 2018 and May 2023
Time frame: Up to approximately 4 years and 6 months
Median Treatment Duration
Time frame: Up to approximately 4 years and 6 months
Median Time to Next Treatment (TTNT)
TTNT was calculated considering the time between the start of one treatment line and the start of the next treatment line.
Time frame: Up to approximately 4 years and 6 months
Number of Patients With Dose Reductions by Treatment Length per Line of Treatment
Patients were categorized as having 0, 1, or 2 dose reductions over 0-6 months, 7-12 months, and 12 months or more of treatment.
Time frame: Up to approximately 4 years and 6 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.